Psoriasis News Archive
Mild, moderate, and severe psoriasis can patients' quality of life and workplace productivity.
Patients with psoriasis are more likely to have an abdominal aortic aneurysm, with the likelihood increasing with more severe psoriasis.
Researchers found that the annual incidence rate of PsA was 2.7 cases per 100 psoriasis patients.
Escalating prices were found across all categories of dermatologic drugs, including anti-infective medications and treatments for psoriasis and rosacea.
Only 10% of Medicare beneficiaries were receiving biologic treatments for psoriasis.
El Nino and La Nina have been linked to increases in actinic keratosis, rosacea, dermatitis, psoriasis, and varicella, among other dermatologic conditions.
Patients with psoriasis or psoriatic arthritis who undergo bariatric surgery may see significant improvements in disease severity.
Biologic agents associated with high risk of hepatitis B virus flares in patients with psoriasis or rheumatoid arthritis
The use of biologic agents in treatment of patients rheumatoid arthritis or psoriasis is associated with a significant risk of heptatis B flares.
Combination use of methotrexate and golimumab may significantly improve psoriatic arthritis symptoms
Using methotrexate and golimumab in combination may significantly improve some symptoms among patients diagnoes with psoriatic arthritis.
Several controlled clinical trials have proven the efficacy of golimumab in reducing symptom severity and improving disease outcomes in patients with psoriatic arthritis.
Many people think that psoriasis is contagious or that it is caused by an infection, which contribute to the stigma.
The most severe cases of psoriasis can increase vascular inflammation levels by as much as 41%.
Another study linked psoriasis to major depression, but the results still do not show a causal effect.
Two studies indicate that brodalumab and secukinumab had significant benefits for patients with psoriasis or psoriatic arthritis.
Patients with psoriasis, especially those with psoriatic arthritis, have an increased risk of arrhythmia.
Adding kunzea oil to topical psoriasis treatments did not improve their efficacy.
Patients with psoriasis who take biologic medications report more overall treatment satisfaction.
The safety and efficacy of 56 treatment courses for pediatric psoriasis were evaluated.
Women with psoriasis and psoriatic arthritis have an increased risk of depression.
Alefacept, a psoriasis treatment, can help preserve pancreas function in type 1 diabetes.
Psoriasis patients exposed to trauma have an increased risk for psoriatic arthritis.
Patients and practitioners require significant education about psoriasis, including information on treatment options.
The monoclonal antibody ixekizumab was more effective than other treatments for treating psoriasis.
Guselkumab was more effective than standard psoriasis treatment but had higher rates of pneumonia.
People with newly diagnosed psoriatic arthritis have an increased risk of later CVD.
Nearly 20% of patients lost more than 5% of their baseline weight by 52 weeks or less when assigned to receive apremilast.
Patients with psoriasis should avoid long-term use of medications that are toxic to the kidneys.
Patient with psoriasis were unsuccessfully treated with conventional therapies before treatment with biologics.
Patients with psoriasis do not have an increased of major cardiovascular events like heart attack and stroke.
Patients taking adalimumab saw quicker treatment of their psoriasis than those taking methotrexate.
Male patients with psoriasis have higher levels of estradiol and lower levels of testosterone compared with controls.
The rate of reported adverse events was comparable in both the treatment and placebo groups.
It is estimated that 30% to 60% of children with juvenile psoriasis develop plaque psoriasis, according to the researchers.
The preferred order for combining a second modality with biologics is biologic and methotrexate combination, biologic and acitretin combination, and then biologic and phototherapy combination.
These study findings confirm that the therapeutic silencing of IL-23 is a potential target for psoriasis prevention and management.
Consistent evidence supports the use of fish oil supplementation. Zinc supplementation, however, has not been proven effective.
The presence of snoring was not associated with a higher risk of psoriasis.
This discovery could prevent progression of psoriatic arthritis in patients with psoriasis.
Infliximab and ustekinumab 90 mg were the most costly therapies.
The 31 patients who received BI 655066 had clinical improvement beginning at week 2 and maintained through week 66 weeks.
The prevalence of H. pylori was not higher in psoriasis versus the control, but patients infected with H. pylori showed more severe psoriasis compared with uninfected patients.
Providers may have not made changes to treatment strategies due to the high effectiveness of biologics in most visits.
The dermatitis patient can be extremely complex in their presentation, as well as have multiple dermatoses complicating the diagnosis.
The coexistence of psoriasis with lupus erythematosus is rare and often presents a therapeutic challenge.
Topical corticosteroids and ultraviolet therapies are still proving to be strong competitors in psoriasis treatment.
The initial site of articular inflammation is where the Achilles tendon attaches to the bone.
The long-term safety profile of continuous fumaric acid esters treatment is favorable.
Less likely to engage in moderate to vigorous physical activity, especially those with severe disease
The causative link between chronic tonsillitis and psoriasis have been mostly speculative based on translational association studies.
Secukinumab has been approved by the FDA for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.
Educational programs may improve cardiovascular and metabolic risk management in patients.
Agents in biologic monotherapy target key processes in the pathogenesis of psoriasis, therefore offering better efficacy than current biologic and systemic therapies.
Direct costs of psoriasis ranged from $51.7 billion to $63.2 billion, and indirect costs ranged from $23.9 billion to $35.4 billion.
Clinicians who treat patients with psoriasis may need additional training in lifestyle behavior modification initiatives.
Patients with certain autoimmune diseases have a higher risk for varicella zoster infection, but the rates were not significant among patients with psoriasis.
Overweight and obese psoriasis patients should to lose weight and increase physical activity as a way to improve psoriasis symptoms.
The increased risk of CKD and GN was seen in patients with both mild and severe psoriasis.
Beta-blockers are known to induce or aggravate psoriasis and should be avoided in these patients whenever possible.
Provide screening and counseling to address the impact of alcohol and tobacco use in patients with psoriasis.
Dermatological experts developed four clinical nail psoriasis scenarios for clinicians.
The prevalence of advanced liver fibrosis was 8.1% in patients with psoriasis, compared with only 3.6% in the control group.
The incidence of deep fungal infections has risen with the increase of biologic treatment in psoriasis patients.
Brodalumab completely cleared the skin of more patients with psoriasis in a 3-month period than Stelera.
All subjects successfully self-administered treatment at Week 1, without critical use-related hazards.
Cardiovascular risk is increased in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis.
An estimated 60% of study participants with psoriasis had uncontrolled hypertension.
Research into blocking specific steps in certain pathways between the nervous system and the skin could lead to improved treatment of some skin disorders.
Sacroiliitis predicted vascular inflammation beyond psoriatic arthritis and cardiovascular risk factors.
Researchers analyzed cancer rates for different psoriasis treatments, but did not find a significantly greater risk associated with any particular therapy.
Results of a recent study suggest targeting these cells may be a way to prevent and treat psoriasis.
Treatment with TNF-alpha inhibitors demonstrated no increased risk of major cardiac events.
Disease-modifying antirheumatic drug treatments are often discontinued, changed, or added-on to in patients with psoriatic arthritis.
In-patient treatment and nail involvement were the strongest predictors of future PsA.
Determining the ideal blood serum level could translate to improved outcomes for patients with PsA.
Half of the patients in the study were newly diagnosed with four or more symptoms of metabolic syndrome.
Losing weight while taking biologics for psoriatic arthritis (PsA) resulted in greater symptom improvement among obese/overweight compared than no weight loss.
The test identified whether all patients in the study had either dermatologic condition correctly.
Rheumatologists, dermatologists, and patient representatives collaborated to draft these first-ever guidelines.
Worse patient-reported outcomes, shorter treatment adherence, and poorer response to treatment among smokers.
Only about 20% of patients with psoriasis were seen by their health-care provider for follow up within one to two weeks after an initial visit.
Researchers are investigating ways to mediate the interactions between immune cells and nerves.
PsA prevalence based on the patient-administered screening tools was 12% to 16% higher compared with rheumatologists' diagnosis.
AhR signaling in nonhematopoietic cells plays a pivotal role in prevention of excessive skin inflammation.
The resolution sends a powerful global message about the serious nature of the disease.
Data from two randomized trials demonstrate efficacy of secukinumab versus placebo.
Psoriasis flares were seen in female patients prescribed hypertension medication.
Studies suggest that omega-3 fatty acids may be beneficial as monotherapy or in combination with other therapeutic regimens.
Promising investigational oral drug may offer fewer side effects than current therapies.
Improvement rates were similar among treatment-experienced patients and those naive to biologic treatment.
AP1S3 variants were present in a significant number of patients with acrodermatitis continua of Hallopeau.
Although thickness of epicardial fat was significantly higher in patients with psoriasis, it may not benefit as a single marker for psoriasis.
Improvements were noted in patients' physical function, enthesitis, dactylitis, and skin manifestations in a five-year trial.
One year after psoriasis onset, 92% of study participants were overweight or obese.
Treatment adherence is not always consistent, and new adherence patterns may result in more useful classifications.
Nearly 30% of patients lost at least one partial work day because of health concerns related to psoriatic arthritis.
Brodalumab binds to the IL-17 receptor and inhibits inflammatory signaling by blocking the binding of several IL-17 ligands to the receptor.
Nearly twice as many patients with both psoriasis and PsA rated their disease as severe compared with those with psoriasis alone.
Inflammatory crystal arthopathy should be considered in psoriasis patients with PsA.
Smoking is an independent risk factor for developing psoriasis.
A significant discrepancy exists between guidelines and actual practice.